Dr Joël Richard is presently having the position of Chief Development Officer in Enterome, leading CMC, Non-Clinical and Regulatory activities. He has 30 years of experience in biopharmaceutical R&D, including several previous global senior leadership positions in various Biotech and Pharma companies, such as MedinCell, Ipsen, Merck Serono, Serono and Ethypharm, leading Drug Development Operations of these companies. Dr Richard has more than, 20 years of experience in the Pharmaceutical Development and Industrialization activities for Peptides and Biologics. Dr Richard graduated from Ecole Normale Supérieure (Paris-Saclay, France). He has got his PhD in Materials Science/Colloids & Interface Science from University of Paris and “Habilitation à Diriger les Recherches” (HDR) in Chemistry from University of Bordeaux. He also had an entrepreneurial experience, co-funding with Pr Jean-Pierre Benoit and leading the Mainelab Company (Angers, France), a drug delivery company specialized in the discovery and development of solvent-free processes for protein delivery systems. In the past 20 years, Dr Richard has focused his scientific activities on new formulations and drug delivery systems (such as microspheres, nanoparticles, gelling and self-assembling systems, chemically modified proteins, supercritical fluid technology . . .), especially for injectable protein and peptide formulations. Dr Richard has published 75 peer-reviewed scientific papers, 8 book chapters and 2 editorials in various fields (colloids and interfaces, drug delivery, supercritical fluids, protein and peptides formulations, sustained-release formulations…). He is the author of 125 invited international conferences, 50 international communications and 55 international patent families.